<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766437</url>
  </required_header>
  <id_info>
    <org_study_id>OPTICA</org_study_id>
    <nct_id>NCT04766437</nct_id>
  </id_info>
  <brief_title>Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy</brief_title>
  <acronym>OPTICA</acronym>
  <official_title>Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12-inhibitor,&#xD;
      reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent&#xD;
      implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given&#xD;
      the advances in stent properties, stenting implantation technique and pharmacology, it may be&#xD;
      possible to treat patients with a single antiplatelet strategy using a potent P2Y12-&#xD;
      inhibitor such as prasugrel.&#xD;
&#xD;
      Objective: This study will serve as a pilot to investigate the feasibility and safety of a&#xD;
      single antiplatelet strategy with prasugrel prior to, during and after stent implantation in&#xD;
      75 patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS).&#xD;
&#xD;
      Study design: Single arm pilot study with a stopping rule based on the occurrence of definite&#xD;
      stent thrombosis&#xD;
&#xD;
      Study population: Patients presenting with non-ST segment elevation acute coronary syndrome&#xD;
      and (a) 'de novo' lesion(s) treated with new generation drug-eluting stent(s) with adequate&#xD;
      reduction of platelet reactivity according to platelet function testing with VerifyNow and&#xD;
      optimal stenting result adjudicated by optical coherence tomography or coronary angiography.&#xD;
&#xD;
      Intervention: Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg&#xD;
      prasugrel at least 2 hours prior to percutaneous coronary intervention (PCI) without&#xD;
      concurrent aspirin therapy.&#xD;
&#xD;
      Main study endpoint: The primary ischemic endpoint is the composite of all-cause mortality,&#xD;
      myocardial infarction, Academic Research Consortium defined stent thrombosis and ischemic&#xD;
      stroke at 6 months after percutaneous coronary intervention. The primary bleeding outcome is&#xD;
      major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5&#xD;
      bleeding at 6 months after percutaneous coronary intervention.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 19, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary ischemic endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with primary ischemic endpoint defined as composite of all-cause mortality, myocardial infarction, Academic Research Consortium defined stent thrombosis and ischemic stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary bleeding endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with primary bleeding endpoint defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Non ST Segment Elevation Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 10mg</intervention_name>
    <description>Once daily 10 mg prasugrel for 12 months preceded by a loading dose of 60 mg prasugrel at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.</description>
    <arm_group_label>Prasugrel monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NSTE-ACS diagnosis&#xD;
&#xD;
          -  'De novo' coronary lesion(s) eligible for PCI&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or contraindication for prasugrel use.&#xD;
&#xD;
          -  Concurrent use of oral anticoagulants&#xD;
&#xD;
          -  Overwriting indication for DAPT&#xD;
&#xD;
          -  Planned surgical intervention within 12 months of planned revascularization&#xD;
&#xD;
          -  PCI of left main disease, chronic total occlusion, bifurcation lesion requiring&#xD;
             two-stent treatment, saphenous or arterial graft lesion, severely calcified lesions&#xD;
&#xD;
          -  Recent or ongoing strong CYP3A4 inhibitor or inducer therapy&#xD;
&#xD;
          -  Pregnant or breastfeeding women at time of enrolment&#xD;
&#xD;
          -  Participation in another trial with an investigational drug or device (i.e. stent)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>J.P.S. Henriques, MD PhD</last_name>
    <phone>+31205662857</phone>
    <email>j.p.henriques@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>N.M.R. van der Sangen, MD</last_name>
    <phone>+31205662857</phone>
    <email>n.m.r.vandersangen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels van der Sangen</last_name>
      <email>n.m.r.vandersangen@amsterdamumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 21, 2021</last_update_submitted>
  <last_update_submitted_qc>February 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.P.S Henriques</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non ST Segment Elevation Acute Coronary Syndrome</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Prasugrel monotherapy</keyword>
  <keyword>P2Y12-inhibitor monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

